THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)

THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)

Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonogra...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A255-A256
Hauptverfasser: Jousse-Joulin, S., Devauchelle-Pensec, V., Cornec, D., Marhadour, T., Bressolette, L., Pers, J.-O., Nowak, E., Saraux, A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A256
container_issue Suppl 3
container_start_page A255
container_title Annals of the rheumatic diseases
container_volume 72
creator Jousse-Joulin, S.
Devauchelle-Pensec, V.
Cornec, D.
Marhadour, T.
Bressolette, L.
Pers, J.-O.
Nowak, E.
Saraux, A.
description Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonography. Objectives We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients (TEARS study: Tolerance and EfficAcy of Rituximab in pSS)) and we evaluated in a single centre (Brest, France) the echostructural and vascularisation changes in this population. Methods The TEARS study included pSS patients with scores above 50 mmon at least two of four visual analog scales (VASs) evaluating dryness, pain, fatigue, and global disease. They were randomly assigned (1:1) to RTX (1 gat weeks 0 and 2) or placebo. Patient had recent-onset (
doi_str_mv 10.1136/annrheumdis-2013-eular.795
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777911773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008752301</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1633-c7afa1310ade84057f447d7d68ee0ca37794a361d71e6b50d3abb6576dc9f8343</originalsourceid><addsrcrecordid>eNqVkEtOwzAURS0EEqWwBwsmMAjYOLFTZhBBi0CAaAtD6yV2ICV1ip0gOkNIbIkNsBNWgksQYsrEP537rnwQ2qRkl1LG98AYe6-bqSpcsE8oC3RTgt0VvWgJdWjIY__KyTLqEEJYEPa4WEVrzk38lcQ07qDX0WBM9rn4fHkbl7UFV5nqzsLsvsjwEMriCewc90swyuFr7WaVcRrXFb4u6ua5mEKKC4OvrD95bjj5eO9bbfBwbpStphpfQV1oUzu8PdJgHR768X8K6kbNd9bRSg6l0xs_exeNT45HySA4v-yfJofnQUo5Y0EmIAfKKAGl45BEIg9DoYTisdYkAyZELwTGqRJU8zQiikGa8khwlfXymIWsi7bauTNbPTba1XJSNdb4SkmFT1O_Mk8dtFRmK-eszuWs_Z2kRC6cyz_O5cK5_HYuvXMfDtpw4Wr9_JsE-yC5YCKSFzeJTJIR69_eHskzz0ctn04n_-n5AoiVn7M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777911773</pqid></control><display><type>article</type><title>THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)</title><source>BMJ Journals - NESLi2</source><creator>Jousse-Joulin, S. ; Devauchelle-Pensec, V. ; Cornec, D. ; Marhadour, T. ; Bressolette, L. ; Pers, J.-O. ; Nowak, E. ; Saraux, A.</creator><creatorcontrib>Jousse-Joulin, S. ; Devauchelle-Pensec, V. ; Cornec, D. ; Marhadour, T. ; Bressolette, L. ; Pers, J.-O. ; Nowak, E. ; Saraux, A.</creatorcontrib><description>Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonography. Objectives We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients (TEARS study: Tolerance and EfficAcy of Rituximab in pSS)) and we evaluated in a single centre (Brest, France) the echostructural and vascularisation changes in this population. Methods The TEARS study included pSS patients with scores above 50 mmon at least two of four visual analog scales (VASs) evaluating dryness, pain, fatigue, and global disease. They were randomly assigned (1:1) to RTX (1 gat weeks 0 and 2) or placebo. Patient had recent-onset (&lt;10 years) biologically active pSS and/or systemic pSS. 28 pSS patients had ultrasonographic examination before the first infusion (placebo or RTX) and at 24 weeks follow up. Both parotid and submandibular glands were assessed. The echostructure of each gland was scored using a semi quantitative scoring (0 to 4). We also evaluated the size of each glands and the vascularisation using the resistive index of the transverse facial artery of the parotid glands before and after stimulation with lemon juice. Concerning the echostructural scoring of each gland, we considered an improvement if the score of the glands was improved by one point or more and the comparison between the RTX and placebo group were obtained using the Fisher’s exact test. Difference of size (mm) and resistive index before and after treatment (RTX or placebo) were evaluated using the non parametric Wilcoxon test. Results Using this methodology, parotid echostructural scoring was improved in 50% of pSS patients in the RTX group versus 7% in the placebo group (p=0.03). The US submandibular scoring was also improved in 35% of pSS patients in the RTX group compared to 16% in the placebo but the difference was not statistically significant (p= 0.16). There were no changes concerning the size of each gland in RTX or placebo groups. Regarding the modifications between week 0 and week 24 of lemon stimulation response, measured by resistive index variation before and after stimulation, the two groups were not different. Conclusions In our pSS population treated by RTX or placebo, ultrasound evaluation showed a more important improvement of the echo structure of the salivary glands in treated patients than in the placebo group. In contrast, RTX did not modify neither sizes of the salivary glands nor vascularisation inside the glands. References Cornec D, Jousse-Joulin S, Pers JO, Marhadour T, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: Toward new diagnostic criteria?Arthritis Rheum. 2013 ;65:216-25. Acknowledgements Financial support for this study was received from the Programme Hospitalier de Recherche Clinique (PHRC) 2010. Rituximab was donated free of charge by Roche. Disclosure of Interest S. Jousse-Joulin: None Declared, V. Devauchelle-Pensec Grant/research support from: Roche, D. Cornec: None Declared, T. Marhadour: None Declared, L. Bressolette: None Declared, J.-O. Pers: None Declared, E. Nowak: None Declared, A. Saraux Grant/research support from: Roche, Speakers bureau: Roche</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2013-eular.795</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><ispartof>Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A255-A256</ispartof><rights>2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2013 (c) 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A255.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/72/Suppl_3/A255.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Jousse-Joulin, S.</creatorcontrib><creatorcontrib>Devauchelle-Pensec, V.</creatorcontrib><creatorcontrib>Cornec, D.</creatorcontrib><creatorcontrib>Marhadour, T.</creatorcontrib><creatorcontrib>Bressolette, L.</creatorcontrib><creatorcontrib>Pers, J.-O.</creatorcontrib><creatorcontrib>Nowak, E.</creatorcontrib><creatorcontrib>Saraux, A.</creatorcontrib><title>THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonography. Objectives We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients (TEARS study: Tolerance and EfficAcy of Rituximab in pSS)) and we evaluated in a single centre (Brest, France) the echostructural and vascularisation changes in this population. Methods The TEARS study included pSS patients with scores above 50 mmon at least two of four visual analog scales (VASs) evaluating dryness, pain, fatigue, and global disease. They were randomly assigned (1:1) to RTX (1 gat weeks 0 and 2) or placebo. Patient had recent-onset (&lt;10 years) biologically active pSS and/or systemic pSS. 28 pSS patients had ultrasonographic examination before the first infusion (placebo or RTX) and at 24 weeks follow up. Both parotid and submandibular glands were assessed. The echostructure of each gland was scored using a semi quantitative scoring (0 to 4). We also evaluated the size of each glands and the vascularisation using the resistive index of the transverse facial artery of the parotid glands before and after stimulation with lemon juice. Concerning the echostructural scoring of each gland, we considered an improvement if the score of the glands was improved by one point or more and the comparison between the RTX and placebo group were obtained using the Fisher’s exact test. Difference of size (mm) and resistive index before and after treatment (RTX or placebo) were evaluated using the non parametric Wilcoxon test. Results Using this methodology, parotid echostructural scoring was improved in 50% of pSS patients in the RTX group versus 7% in the placebo group (p=0.03). The US submandibular scoring was also improved in 35% of pSS patients in the RTX group compared to 16% in the placebo but the difference was not statistically significant (p= 0.16). There were no changes concerning the size of each gland in RTX or placebo groups. Regarding the modifications between week 0 and week 24 of lemon stimulation response, measured by resistive index variation before and after stimulation, the two groups were not different. Conclusions In our pSS population treated by RTX or placebo, ultrasound evaluation showed a more important improvement of the echo structure of the salivary glands in treated patients than in the placebo group. In contrast, RTX did not modify neither sizes of the salivary glands nor vascularisation inside the glands. References Cornec D, Jousse-Joulin S, Pers JO, Marhadour T, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: Toward new diagnostic criteria?Arthritis Rheum. 2013 ;65:216-25. Acknowledgements Financial support for this study was received from the Programme Hospitalier de Recherche Clinique (PHRC) 2010. Rituximab was donated free of charge by Roche. Disclosure of Interest S. Jousse-Joulin: None Declared, V. Devauchelle-Pensec Grant/research support from: Roche, D. Cornec: None Declared, T. Marhadour: None Declared, L. Bressolette: None Declared, J.-O. Pers: None Declared, E. Nowak: None Declared, A. Saraux Grant/research support from: Roche, Speakers bureau: Roche</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkEtOwzAURS0EEqWwBwsmMAjYOLFTZhBBi0CAaAtD6yV2ICV1ip0gOkNIbIkNsBNWgksQYsrEP537rnwQ2qRkl1LG98AYe6-bqSpcsE8oC3RTgt0VvWgJdWjIY__KyTLqEEJYEPa4WEVrzk38lcQ07qDX0WBM9rn4fHkbl7UFV5nqzsLsvsjwEMriCewc90swyuFr7WaVcRrXFb4u6ua5mEKKC4OvrD95bjj5eO9bbfBwbpStphpfQV1oUzu8PdJgHR768X8K6kbNd9bRSg6l0xs_exeNT45HySA4v-yfJofnQUo5Y0EmIAfKKAGl45BEIg9DoYTisdYkAyZELwTGqRJU8zQiikGa8khwlfXymIWsi7bauTNbPTba1XJSNdb4SkmFT1O_Mk8dtFRmK-eszuWs_Z2kRC6cyz_O5cK5_HYuvXMfDtpw4Wr9_JsE-yC5YCKSFzeJTJIR69_eHskzz0ctn04n_-n5AoiVn7M</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Jousse-Joulin, S.</creator><creator>Devauchelle-Pensec, V.</creator><creator>Cornec, D.</creator><creator>Marhadour, T.</creator><creator>Bressolette, L.</creator><creator>Pers, J.-O.</creator><creator>Nowak, E.</creator><creator>Saraux, A.</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201306</creationdate><title>THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)</title><author>Jousse-Joulin, S. ; Devauchelle-Pensec, V. ; Cornec, D. ; Marhadour, T. ; Bressolette, L. ; Pers, J.-O. ; Nowak, E. ; Saraux, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1633-c7afa1310ade84057f447d7d68ee0ca37794a361d71e6b50d3abb6576dc9f8343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jousse-Joulin, S.</creatorcontrib><creatorcontrib>Devauchelle-Pensec, V.</creatorcontrib><creatorcontrib>Cornec, D.</creatorcontrib><creatorcontrib>Marhadour, T.</creatorcontrib><creatorcontrib>Bressolette, L.</creatorcontrib><creatorcontrib>Pers, J.-O.</creatorcontrib><creatorcontrib>Nowak, E.</creatorcontrib><creatorcontrib>Saraux, A.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jousse-Joulin, S.</au><au>Devauchelle-Pensec, V.</au><au>Cornec, D.</au><au>Marhadour, T.</au><au>Bressolette, L.</au><au>Pers, J.-O.</au><au>Nowak, E.</au><au>Saraux, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>72</volume><issue>Suppl 3</issue><spage>A255</spage><epage>A256</epage><pages>A255-A256</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Ultrasound (US) is a non-invasive tool validated to identify structural abnormalities of salivary glands and to diagnose primary Sjögren Syndrome patients (pSS) (1). However, no previous study evaluated the follow up and the potential improvement of treated pSS patients using ultrasonography. Objectives We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy of Rituximab (RTX) in active pSS patients (TEARS study: Tolerance and EfficAcy of Rituximab in pSS)) and we evaluated in a single centre (Brest, France) the echostructural and vascularisation changes in this population. Methods The TEARS study included pSS patients with scores above 50 mmon at least two of four visual analog scales (VASs) evaluating dryness, pain, fatigue, and global disease. They were randomly assigned (1:1) to RTX (1 gat weeks 0 and 2) or placebo. Patient had recent-onset (&lt;10 years) biologically active pSS and/or systemic pSS. 28 pSS patients had ultrasonographic examination before the first infusion (placebo or RTX) and at 24 weeks follow up. Both parotid and submandibular glands were assessed. The echostructure of each gland was scored using a semi quantitative scoring (0 to 4). We also evaluated the size of each glands and the vascularisation using the resistive index of the transverse facial artery of the parotid glands before and after stimulation with lemon juice. Concerning the echostructural scoring of each gland, we considered an improvement if the score of the glands was improved by one point or more and the comparison between the RTX and placebo group were obtained using the Fisher’s exact test. Difference of size (mm) and resistive index before and after treatment (RTX or placebo) were evaluated using the non parametric Wilcoxon test. Results Using this methodology, parotid echostructural scoring was improved in 50% of pSS patients in the RTX group versus 7% in the placebo group (p=0.03). The US submandibular scoring was also improved in 35% of pSS patients in the RTX group compared to 16% in the placebo but the difference was not statistically significant (p= 0.16). There were no changes concerning the size of each gland in RTX or placebo groups. Regarding the modifications between week 0 and week 24 of lemon stimulation response, measured by resistive index variation before and after stimulation, the two groups were not different. Conclusions In our pSS population treated by RTX or placebo, ultrasound evaluation showed a more important improvement of the echo structure of the salivary glands in treated patients than in the placebo group. In contrast, RTX did not modify neither sizes of the salivary glands nor vascularisation inside the glands. References Cornec D, Jousse-Joulin S, Pers JO, Marhadour T, et al. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: Toward new diagnostic criteria?Arthritis Rheum. 2013 ;65:216-25. Acknowledgements Financial support for this study was received from the Programme Hospitalier de Recherche Clinique (PHRC) 2010. Rituximab was donated free of charge by Roche. Disclosure of Interest S. Jousse-Joulin: None Declared, V. Devauchelle-Pensec Grant/research support from: Roche, D. Cornec: None Declared, T. Marhadour: None Declared, L. Bressolette: None Declared, J.-O. Pers: None Declared, E. Nowak: None Declared, A. Saraux Grant/research support from: Roche, Speakers bureau: Roche</abstract><cop>Kidlington</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><doi>10.1136/annrheumdis-2013-eular.795</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2013-06, Vol.72 (Suppl 3), p.A255-A256
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1777911773
source BMJ Journals - NESLi2
title THU0267 Ultrasonographic Salivary Glands Response to Rituximab in Primary SjöGren Syndrome Patients (Tears Sononographic Study)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T06%3A02%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=THU0267%E2%80%85Ultrasonographic%20Salivary%20Glands%20Response%20to%20Rituximab%20in%20Primary%20Sj%C3%B6Gren%20Syndrome%20Patients%20(Tears%20Sononographic%20Study)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Jousse-Joulin,%20S.&rft.date=2013-06&rft.volume=72&rft.issue=Suppl%203&rft.spage=A255&rft.epage=A256&rft.pages=A255-A256&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2013-eular.795&rft_dat=%3Cproquest_cross%3E4008752301%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777911773&rft_id=info:pmid/&rfr_iscdi=true